CDSCO tells pharmacies to tighten prescription checks for painkillers and antibiotics
India’s drug regulator has directed pharmacies, retailers, distributors, doctors and hospitals to enforce prescription-only sales of Schedule H NSAIDs and Schedule H1 antibiotics, stepping up action against self-medication and antimicrobial resistance.
What happened
Central Drugs Standard Control Organisation (CDSCO) · CDSCO directed Indian pharmacies, retailers, distributors, doctors and hospitals to enforce
Key facts
- September 21
- Schedule H
- Schedule H1
- Drugs Rules, 1945
- Drugs and Cosmetics Act, 1940
Why this matters
Pharmacy platforms and chains may seek compliance-tech, e-prescription and pharmacist-training partnerships to turn stricter prescription enforcement into a trust and differentiation advantage.
What to watch
- CDSCO or state drug-controller inspection notices, penalties, license suspensions or public enforcement disclosures.
- Clarification on acceptable e-prescriptions, prescription retention periods and digital-record requirements.
- A rise in pharmacy-chain investments in pharmacist staffing, prescription-management software and telehealth partnerships.
- Material sequential declines in antibiotic and painkiller unit sales accompanied by gains in consultations, diagnostics or non-restricted analgesics.
- State-level enforcement variation that changes competitive conditions between organized and independent pharmacies.
- Evidence of online pharmacy delivery restrictions or platform-level prescription-upload mandates.
- Implement mandatory prescription verification and retention workflows for Schedule H and H1 products across stores, apps and delivery channels.
- Train pharmacists, cashiers and delivery staff on restricted-SKU identification, escalation rules and refusal procedures.
- Audit inventory, billing and POS controls to block dispensing without required prescription fields and pharmacist authorization.
- Expand teleconsultation, e-prescription and doctor-referral partnerships to reduce customer friction.
- Track category-level sales declines, prescription attachment rates, rejected transactions and repeat inspection findings by location.
- Review distributor documentation and returns processes to ensure restricted-medicine traceability.